Characterization of AJH-836, a diacylglycerol-lactone with selectivity for novel PKC isozymes

Diacylglycerol (DAG) is a key lipid second messenger downstream of cellular receptors that binds to the C1 domain in many regulatory proteins. Protein kinase C (PKC) isoforms constitute the most prominent family of signaling proteins with DAG-responsive C1 domains, but six other families of proteins, including the chimaerins, Ras-guanyl nucleotide–releasing proteins (RasGRPs), and Munc13 isoforms, also play important roles. Their significant involvement in cancer, immunology, and neurobiology has driven intense interest in the C1 domain as a therapeutic target. As with other classes of targets, however, a key issue is the establishment of selectivity. Here, using [3H]phorbol 12,13-dibutyrate ([3H]PDBu) competition binding assays, we found that a synthetic DAG-lactone, AJH-836, preferentially binds to the novel PKC isoforms PKCδ and PKCϵ relative to classical PKCα and PKCβII. Assessment of intracellular translocation, a hallmark for PKC activation, revealed that AJH-836 treatment stimulated a striking preferential redistribution of PKCϵ to the plasma membrane relative to PKCα. Moreover, unlike with the prototypical phorbol ester phorbol 12-myristate 13-acetate (PMA), prolonged exposure of cells to AJH-836 selectively down-regulated PKCδ and PKCϵ without affecting PKCα expression levels. Biologically, AJH-836 induced major changes in cytoskeletal reorganization in lung cancer cells, as determined by the formation of membrane ruffles, via activation of novel PKCs. We conclude that AJH-836 represents a C1 domain ligand with PKC-activating properties distinct from those of natural DAGs and phorbol esters. Our study supports the feasibility of generating selective C1 domain ligands that promote novel biological response patterns.

[1]  M. Kazanietz,et al.  5-oxo-ETE activates migration of H295R adrenocortical cells via MAPK and PKC pathways. , 2019, Prostaglandins & other lipid mediators.

[2]  M. Kazanietz,et al.  Differential Regulation of Gene Expression in Lung Cancer Cells by Diacyglycerol-Lactones and a Phorbol Ester Via Selective Activation of Protein Kinase C Isozymes , 2019, Scientific Reports.

[3]  M. Kazanietz,et al.  DISTINCTIVE REQUIREMENT OF PKCε IN THE CONTROL OF Rho GTPases IN EPITHELIAL AND MESENCHYMALLY-TRANSFORMED LUNG CANCER CELLS , 2019, Oncogene.

[4]  M. Kazanietz,et al.  The role of Rac in tumor susceptibility and disease progression: from biochemistry to the clinic. , 2018, Biochemical Society transactions.

[5]  M. Kazanietz,et al.  The Rac GTPase in Cancer: From Old Concepts to New Paradigms. , 2017, Cancer research.

[6]  P. Blumberg,et al.  Synthesis and Evaluation of Dimeric Derivatives of Diacylglycerol-Lactones as Protein Kinase C Ligands. , 2017, Bioconjugate chemistry.

[7]  Megan L. Peach,et al.  Exploring the influence of indololactone structure on selectivity for binding to the C1 domains of PKCα, PKCε, and RasGRP. , 2017, Bioorganic & medicinal chemistry.

[8]  M. Kazanietz,et al.  Protein kinase C in cancer: The top five unanswered questions , 2017, Molecular carcinogenesis.

[9]  J. Blando,et al.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway. , 2017, Cell reports.

[10]  Hyunju Kim,et al.  Protein Kinase C Isoforms Differentially Regulate Hypoxia‐Inducible Factor‐1α Accumulation in Cancer Cells , 2016, Journal of cellular biochemistry.

[11]  A. Kisialiou,et al.  New Drugs from Marine Organisms in Alzheimer’s Disease , 2015, Marine drugs.

[12]  A. Ridley,et al.  Rho GTPase signalling in cell migration , 2015, Current opinion in cell biology.

[13]  P. Blumberg,et al.  Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-lactones). , 2015, European journal of medicinal chemistry.

[14]  M. Kazanietz,et al.  Protein kinase C and cancer: what we know and what we do not , 2014, Oncogene.

[15]  P. Blumberg,et al.  Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP. , 2014, Bioorganic & medicinal chemistry.

[16]  P. Blumberg,et al.  Molecular Systems Pharmacology: Isoelectric Focusing Signature of Protein Kinase Cδ Provides an Integrated Measure of Its Modulation in Response to Ligands , 2014, Journal of medicinal chemistry.

[17]  B. Paluch,et al.  Agonist-induced Down-regulation of Endogenous Protein Kinase C α through an Endolysosomal Mechanism* , 2013, The Journal of Biological Chemistry.

[18]  K. Das,et al.  Protein kinase C, an elusive therapeutic target? , 2012, Nature Reviews Drug Discovery.

[19]  M. Kazanietz,et al.  Proteins kinase Cɛ is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes , 2012, Oncogene.

[20]  J. Kissil,et al.  Non-Small Cell Lung Carcinoma Cell Motility, Rac Activation and Metastatic Dissemination Are Mediated by Protein Kinase C Epsilon , 2012, PloS one.

[21]  M. Kazanietz,et al.  p23/Tmp21 Associates with Protein Kinase Cδ (PKCδ) and Modulates Its Apoptotic Function* , 2011, The Journal of Biological Chemistry.

[22]  M. Kazanietz,et al.  Bryostatin 1 Inhibits Phorbol Ester-Induced Apoptosis in Prostate Cancer Cells by Differentially Modulating Protein Kinase C (PKC) δ Translocation and Preventing PKCδ-Mediated Release of Tumor Necrosis Factor-α , 2010, Molecular Pharmacology.

[23]  A. Newton,et al.  Protein kinase C: poised to signal. , 2010, American journal of physiology. Endocrinology and metabolism.

[24]  Michael A Gorin,et al.  Protein kinase Cε: an oncogene and emerging tumor biomarker , 2009, Molecular Cancer.

[25]  P. Blumberg,et al.  Characterization of the Differential Roles of the Twin C1a and C1b Domains of Protein Kinase Cδ* , 2009, Journal of Biological Chemistry.

[26]  Megan L. Peach,et al.  Conformationally constrained analogues of diacylglycerol. 29. Cells sort diacylglycerol-lactone chemical zip codes to produce diverse and selective biological activities. , 2008, Journal of medicinal chemistry.

[27]  Megan L. Peach,et al.  Wealth of opportunity - the C1 domain as a target for drug development. , 2008, Current drug targets.

[28]  A. Basu,et al.  Protein kinase Cε makes the life and death decision , 2007 .

[29]  P. Parker,et al.  Novel phosphorylation site markers of protein kinase C delta activation , 2007, FEBS letters.

[30]  A. Altman,et al.  Protein kinase C theta (PKCθ) : A key player in T cell life and death , 2007 .

[31]  M. Kazanietz,et al.  Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.

[32]  M. Kazanietz,et al.  C1 domains exposed: from diacylglycerol binding to protein-protein interactions. , 2006, Biochimica et biophysica acta.

[33]  P. Blumberg,et al.  A Novel Diacylglycerol-lactone Shows Marked Selectivity in Vitro among C1 Domains of Protein Kinase C (PKC) Isoforms α and δ as Well as Selectivity for RasGRP Compared with PKCα* , 2005, Journal of Biological Chemistry.

[34]  W. Lu,et al.  Roles of Tyrosine Phosphorylation and Cleavage of Protein Kinase Cδ in Its Protective Effect Against Tumor Necrosis Factor-related Apoptosis Inducing Ligand-induced Apoptosis* , 2005, Journal of Biological Chemistry.

[35]  R. Begley,et al.  Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. , 2004, Biochemical and biophysical research communications.

[36]  H. Matsuzaki,et al.  Ceramide-induced Apoptosis by Translocation, Phosphorylation, and Activation of Protein Kinase Cδ in the Golgi Complex* , 2004, Journal of Biological Chemistry.

[37]  D. Hamer,et al.  Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. , 2003, Antiviral research.

[38]  P. Blumberg,et al.  Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C). , 2003, Accounts of chemical research.

[39]  T. Kuroki,et al.  Protein kinase C eta (PKC eta): its involvement in keratinocyte differentiation. , 2002, Journal of biochemistry.

[40]  Victor E. Marquez,et al.  Diacylglycerol (DAG)-lactones, a New Class of Protein Kinase C (PKC) Agonists, Induce Apoptosis in LNCaP Prostate Cancer Cells by Selective Activation of PKCα* , 2002, The Journal of Biological Chemistry.

[41]  B Bienfait,et al.  Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C? , 2000, Journal of medicinal chemistry.

[42]  P. Blumberg,et al.  Differential Localization of Protein Kinase C δ by Phorbol Esters and Related Compounds Using a Fusion Protein with Green Fluorescent Protein* , 1999, The Journal of Biological Chemistry.

[43]  P. Parker,et al.  The extended protein kinase C superfamily. , 1998, The Biochemical journal.

[44]  Z. Szallasi,et al.  Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase Cdelta: possible correlation with tumor-promoting activity. , 1998, Cancer research.

[45]  J. Hurley,et al.  Crystal structure of the Cys2 activator-binding domain of protein kinase Cδ in complex with phorbol ester , 1995, Cell.

[46]  L. Dekker,et al.  Protein kinase C (PKC)-induced PKC degradation: a model for down-regulation. , 1995, Biochemical Society transactions.

[47]  H. Mischak,et al.  Characterization of ligand and substrate specificity for the calcium-dependent and calcium-independent protein kinase C isozymes. , 1993, Molecular pharmacology.

[48]  Z. Szallasi,et al.  Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. , 1993, Cancer research.

[49]  G. Martiny-Baron,et al.  Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. , 1993, The Journal of biological chemistry.

[50]  W. Kolch,et al.  Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. , 1993, The Journal of biological chemistry.

[51]  M. Kazanietz,et al.  Differential irreversible insertion of protein kinase C into phospholipid vesicles by phorbol esters and related activators. , 1992, The Journal of biological chemistry.

[52]  P. Parker,et al.  Identification of multiple PKC isoforms in Swiss 3T3 cells: Differential down‐regulation by phorbol ester , 1992, Journal of cellular physiology.

[53]  Y. Nishizuka,et al.  Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[54]  S. Yuspa,et al.  Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. , 1987, Carcinogenesis.

[55]  Y. Hannun,et al.  Phorbol ester binding and activation of protein kinase C on triton X-100 mixed micelles containing phosphatidylserine. , 1986, The Journal of biological chemistry.

[56]  G. Martiny-Baron,et al.  Overexpression of Protein Kinase CS and-6 in NIH 3 T 3 Cells Induces Opposite Effects on Growth , Morphology , Anchorage Dependence , and Tumorigenicity * , 2001 .

[57]  K. Leach,et al.  Competitive inhibition by diacylglycerol of specific phorbol ester binding. , 1984, Proceedings of the National Academy of Sciences of the United States of America.